Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

- candidate number0
- NTR NumberNTR25
- Date ISRCTN created16-mei-2005
- date ISRCTN requested12-apr-2005
- Date Registered NTR2-mrt-2005
- Secondary IDsN/A 
- Public TitleThe European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.
- Scientific TitleThe European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.
- hypothesisWhat is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on (loss of) one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?
- Healt Condition(s) or Problem(s) studiedSchizophrenia, Schizophreniform disorder, Schizoaffective disorder
- Inclusion criteria1. Diagnosis of schizophrenia;
2. Schizophreniform or schizoaffective disorder;
3. Age 18-40 years.
- Exclusion criteria1. A time interval between the onset of positive symptoms (hallucinations and/or delusions) and study entry exceeding two years;
2. Prior use of antipsychotic medication longer than an episode of two weeks in the previous year and/or 6 weeks lifetime;
3. Intolerance to one of the drugs in this study;
4. The presence of one or more of the contraindications against any of the study drugs.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-dec-2002
- planned closingdate1-dec-2006
- Target number of participants500
- InterventionsDrug: Amisulpride 200-800 mg/day
Drug: Haloperidol 1-4 mg/day
Drug: Olanzapine 5-20 mg/day
Drug: Quetiapine 200-750 mg/day
Drug: Ziprasidone 40-160 mg/day
- Primary outcomeRetention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. This outcome is assessed at regular time intervals until 12 months after recruitment.
- Secondary outcomeAt regular time intervals patients are followed-up until 12 months after recruitment: psychopathology (positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation), side effects (EPS side-effect profile, sexual side effects and weight gain), compliance, social needs, quality of life, substance abuse, neurocognitive functioning, and genetic determinants of response to antipsychotic drugs and natural history of schizophrenia.
- Timepoints
- Trial web site
- statusstopped: trial finished
- Sponsor/Initiator EGRIS (European Group for Research in Schizophrenia)
- Funding
(Source(s) of Monetary or Material Support)
Pfizer, AstraZeneca, Sanofi-Aventis
- Publications1. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE for the EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. The Lancet 2008; 371: 1085-1097.

Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophr Res 2005;78:147-56.
- Brief summaryIn the European First Episode Schizophrenia Trial (EUFEST) we study the effectiveness of antipsychotic drugs in patients with recent onset schizophrenia. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention. We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment. The principal investigators are Prof.dr. René S Kahn and Prof.dr. W Wolfgang Fleischhacker.
- Main changes (audit trail)
- RECORD5-jul-2005 - 3-apr-2008

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar
  • Dit zijn de gegevens waarmee uw trial is aangemeld en geregistreerd in het Nederlands Trial Register